Stock EYPT EYEPOINT PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
17.63 USD +5.25% Intraday chart for EyePoint Pharmaceuticals, Inc. +4.01% -23.71%
04-02 EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board CI
03-18 EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer
EyePoint Pharmaceuticals, Inc. Announces Executive Changes
EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
Eyepoint Pharmaceuticals Insider Sold Shares Worth $1,265,539, According to a Recent SEC Filing
Eyepoint Pharmaceuticals Insider Sold Shares Worth $660,370, According to a Recent SEC Filing
Eyepoint Pharmaceuticals Insider Sold Shares Worth $297,621, According to a Recent SEC Filing
Eyepoint Pharmaceuticals Insider Sold Shares Worth $409,790, According to a Recent SEC Filing
Eyepoint Pharmaceuticals Insider Sold Shares Worth $795,191, According to a Recent SEC Filing
Eyepoint Pharmaceuticals Insider Sold Shares Worth $484,124, According to a Recent SEC Filing
EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing
EyePoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing
Eyepoint Pharmaceuticals Insider Sold Shares Worth $990,000, According to a Recent SEC Filing
Eyepoint Pharmaceuticals Insider Sold Shares Worth $415,200, According to a Recent SEC Filing
EyePoint Pharmaceuticals Prices Offering of 11.8 Million Shares to Fund Macular Degeneration Study
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EYPT Stock
  4. News EyePoint Pharmaceuticals, Inc.
  5. Other languages